2-[[(2R)-2-sulfanylpropanoyl]amino]acetic acid

Generic challenges, the next first-to-files, GDUFA dues (FY 2016) and more

PharmaCompass has assessed the second quarter US Drug Master File (DMFs) filings. In our view, with

Wanted: OPPORTUNITIES IN THE DRUG SHORTAGE LIST - APIs urgently needed in US and Canada

Wouldnt it be wonderful if the products that are manufactured, have such great demand that, they fly